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A targeted search for potential drugs of neurotropic action involves the choice of a basic “pharmacophore”, 
which is advisable to carry out on the basis of the achieved principle among the classes of chemical compounds 
where active pharmaceutical substances with high targeted activity have already been identified. Therefore, the 
pyrrolidine core, which is the basic fragment of nootropics of the racetam group, is promising for the rational 
design of biologically active compounds of nootropic action. Its combination with other heterocyclic fragments, 
in particular, the 1,2,4-triazole ring, allows for these “hybrid” molecules to expect a permanent change in the 
magnitude of the pharmacological effects. Creation of a virtual library of compounds, 3D-pharmacophore 
screening and molecular docking is a promising way to optimize a targeted search for substances with a given 
pharmacological activity. 
The aim. To optimize targeted search for new nootropic compounds. 
Materials and methods. The base generation for the virtual screening was carried out using the Marvin Sketch 
20.5 software. For receptor-oriented flexible docking, the Autodock 4.2 software package was used. 
Results. New derivatives of 1-benzyl-4-pyrrolidin-2-one were selected as the object of the study. Based on the 
results of the 3D pharmacophore screening and molecular docking to nootropic targets of the virtual base com-
pounds, scoring functions were calculated. A detailed analysis of the geometrical arrangement of “hit com-
pounds” at the active sites of nootropic receptors (PDB ID: 5UOW, 5CXV, 6PV7) made it possible to formulate 
hypotheses regarding possible ways of interaction of “hybrid” compounds with biotargets. 
The activity of promising molecules with respect to the studied receptors can be realized by creating complexes 
between them, the stability of which is ensured mainly due to the energetically favourable geometric arrange-
ment of ligands in the active center of these acceptors, the formation of hydrogen bonds between them, and in-
termolecular electrostatic and donor-acceptor interactions. 
Conclusions. Structural modification of the pyrrolidine ring by combining with 1,2,4-triazole scaffold contain-
ing substituents of various electronic nature has been proposed. Using 3D-pharmacophore screening, the virtual 
base of 1-benzyl-4-pyrrolidin-2-one derivatives was analyzed in order to search among them for new molecules 
of nootropic action. Docking studies have identified a promising group of derivatives of 1-benzyl-4 (4-R-5-
sulfanylidene-4,5 dihydro-1H-1,2,4-triazol-3-yl) pyrrolidin-2-one, which have affinity for nootropic biotargets 
and are promising for further synthetic and pharmacological studies 
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The search for new chemical structures capable 
of exhibiting specific biological action is a complex 
problem that requires the use of modern methods of 
molecular modelling and it is advisable to carry out in 
the class of chemical compounds where substances with 
a specific directional action have already been identi-
fied. At the research planning stage, we analyzed the 
current range, chemical structure and mechanisms of 
action of existing drugs.  
Currently, there are many drugs with nootropic 
action of different chemical structure, which act on the 
relevant biological targets and, as a consequence, have a 
wide range of pharmacological activity [1, 2]. Ginkgo 
biloba drugs have neuroprotective effects and also act as 
antioxidants and antiapoptotics, inhibiting caspase-3 
activation and amyloid aggregation in the direction of 
Alzheimer's disease. Acetylcholine esterase (AchE) in-
hibitors eliminate the symptoms of Alzheimer's disease. 
However, there is little systematic data on the effect of 
cholinergic treatment on cognitive function in normal 
individuals [3, 4]. Strategies to improve learning and 
memory are aimed at ways to increase the plasticity of 
the brain. Phosphodiesterase inhibitors such as rolipram 
and NMDA-modulating drugs such as donepezil and D-
cycloserine, modafinil and methylphenidate are used to 
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enhance attention and alertness [5, 6]. Referring to the 
fact that most nootropic agents do not have clear mecha-
nisms of action, there is a practical application of most of 
them in the treatment of brain injuries [7].  
Studies of the modern domestic pharmaceutical 
market of nootropic drugs revealed that Ukraine regis-
tered 24 active substances from the list of international 
non-proprietary names of the World Health Organization, 
represented by 107 names [8, 9]. At the same time, do-
mestic drugs prevail in quantitative terms (60.2 %), alt-
hough the main profit from sales is provided by imported 
pharmacotherapeutic nootropic drugs (76 %). Cerebroly-
sin, piracetam and phenotropil are the leaders in the price 
rating of nootropic drugs [10]. 
At the first stage of synthesis planning, in order to 
theoretically substantiate the choice of the basic struc-
ture, we used the accumulated empirical experience, 
logical-structural analysis and “hybrid-pharmacophore 
approach”. The basis of the chemical structure of one of 
the promising groups of psychoactive nootropic drugs of 
the group of racetams (piracetam, aniracetam, oxirace-
tam, pramiracetam, phenylpiracetam, levetiracetam, 
nefiracetam, nebracetam and сoluracetam) is the pyrroli-
dine cycle [11, 12]. Piracetam, a derivative of the neuro-
transmitter γ-aminobutyric acid (GABA), has a variety of 
physiological effects that may be due in part to the resto-
ration of cell membrane fluidity. At the neuronal level, 
piracetam modulates neurotransmission in a number of 
transmitter systems (including cholinergic and glutama-
tergic), has neuroprotective and anticonvulsant proper-
ties, and improves neuroplasticity. At the vascular level, 
it is found that this reduces the adhesion of erythrocytes 
to the vascular endothelium, prevents vasospasm and 
facilitates microcirculation. This diverse range of physio-
logical effects is consistent with its use in a number of 
clinical indications [13, 14]. Piracetam and levetiracetam, 
the S-enantiomer, are derivatives of pyrrolidone that 
have similar chemical structures but have a clear phar-
macological profile and therefore different clinical meth-
ods of application. A brain-specific stereoselective bind-
ing site to which levetiracetam and other S-enantiomers 
have a high affinity has been identified. In preclinical 
studies, piracetam significantly improves learning and 
memory; in contrast, levetiracetam has a lesser effect, but 
is much more active in preventing seizures [15]. Anirace-
tam from the group of racemates activates AMPA recep-
tors and accelerates the synaptic transmission of neural 
messages in the central nervous system. AMPA is a sub-
set of glutamate receptors that are important for neural 
communication, memory formation, and attention. Ani-
racetam enhances the secretion of norepinephrine, dopa-
mine and serotonin, activates acetylcholine receptors and 
has a neuroprotective effect [16].  
The pyrrolidone (2-oxopyrrolidine) family of 
chemicals has been the subject of research for more 
than three decades. Experimental and clinical work 
initially focused on their so-called nootropic effects; 
later there was information about the possibility of 
using their neuroprotection after stroke and use as an-
tiepileptic drugs [17].  
Given the structural similarity with known 
nootropics, further studies of new derivatives of 1-
benzyl-4-pyrrolidin-2-one as a prototype of innovative 
drugs with nootropic action is a very justified approach 
to targeted research. In our opinion, in order to achieve 
biosynergism, it is expedient to chemically modify 1-
benzyl-4-pyrrolidin-2-one by combining in one molecule 
with another "structural matrix", namely the 1,2,4-
triazole ring. Derivatives of 1,2,4-triazole are low-toxic, 
fairly easy to synthesize and highly reactive substances, 
which allows them to be easily combined in one structure 
with other pharmacophore fragments [18]. Scientists in 
European countries refer to the 1,2,4-triazole heterocy-
clic system as a privileged scaffold, as most of the syn-
thesized derivatives of this heterocycle show some phar-
macological activity and are related to different biotar-
gets, which is considered an advantage in the implemen-
tation of the concept of multi-target drugs (concepts of 
multipurpose drugs) [19-20]. Our analysis of the scien-
tific literature showed that despite the large number of 
publications on the functional derivatives of 1,2,4-
triazole and pyrrolidine, the topic of combining them in 
one molecule in the context of “hybrid pharmacophore 
approach” remains virtually unexplored in the literature.  
The therapeutic effect in the absence of the cur-
rently established general molecular mechanism of action 
makes it important to identify common to all nootropic 
drugs receptors and synaptic processes by which they 
have a modulating effect on cognitive functions and 
implement non-specific effects, namely: tranquilizing, 
sedative, hypnotic and psychogogic. Identification of 
these patterns will contribute to the optimization of 
pharmacotherapy of existing drugs and the development 
of new highly effective nootropic agents. It is known that 
the group of racetams has no affinity for tryptamine, 
dopamine, adenosine, opiate, benzodiazepine receptors, 
but is able to affect glutamate and acetylcholine recep-
tors. Therefore, our planned docking studies will target 
these nootropic targets (glutamate receptor (N-methyl-d-
aspartate (NMDAR)) (PDB ID: 5UOW), acetylcholine 
muscarinic and nicotinic receptors (PDB ID: 6PV7, 
5CXV)). 
N-methyl-d-aspartate (NMDAR) receptors are 
heterotetrameric ion channels that are assembled as di-
heteromeric or triheteromeric complexes. The GluN1 / 
GluN2A / GluN2B triheteromeric receptor was selected 
for docking in the presence of a GluN2B-specific allo-
steric modulator Ro 25-6981 (Ro), which was deter-
mined by cryogenic electron microscopy (cryo-EM) 
(PDB ID: 5UOW) [21, 22].  
Nicotinic acetylcholine receptors are pentameric 
ion channels that mediate rapid chemical neurotransmis-
sion. The subtype of nicotinic α3β4 receptors forms the 
main relay between the central and peripheral nervous 
systems in the autonomic ganglia. The nicotinic  
α3β4 receptor in lipid and detergent media was selected 
for docking studies. Receptor structures in complex with 
nicotine, as well as α3β4-selective ligand AT-1001, sup-
plemented by molecular dynamics can predict the selec-
tivity of agonists [23].  
Muscarinic acetylcholine receptors M1-M5 are 
associated with G-proteins and regulate many vital func-
tions of the central and peripheral nervous system. In 
particular, the M1 and M4 receptor subtypes have be-
come targets for new drugs for the treatment of neurolog-
ical disorders such as Alzheimer's disease and schizo-




phrenia. For the study, we selected the crystal structures 
of muscarinic receptors M1 and M4, which are associat-
ed with the inverse agonist - tiotropium [24].  
The aim of the study – to optimize the purpose-
ful search for new compounds of nootropic action.  
 
2. Planning (methodology) of research 
1. At the first stage of purposeful search of new 
nootropic substances in order to theoretically substantiate 
the choice of the basic structure of 1-benzyl-4-pyrrolidin-
2-one, empirical experience, logical-structural analysis 
and “hybrid-pharmacophore approach” were used. 
2. The creation of a virtual database of potential 
nootropic agents was performed by structural modifica-
tion of 1-benzyl-4-pyrrolidin-2-one by a combination 
through position C4 with a substituted 1,2,4-triazole 
system using 3D pharmacophore screening. 
3. The group of racetams is able to affect gluta-
mate at acetylcholine receptors. Therefore, molecular 
docking was targeted at these targets (glutamate receptor 
(N-methyl-d-aspartate (NMDAR)) (PDB ID: 5UOW), 
acetylcholine muscarinic and nicotinic receptors (PDB 
ID: 6PV7, 5CXV)).  
4. The choice of crystallographic models is due to 
the fact that they contained the corresponding ligands. 
This makes it possible to predict the affinity of the stud-
ied molecules to these targets.  
5. Using molecular docking, Scoring functions 
were calculated, which indicate the enthalpy contribution 
to the value of free binding energy (Afinity DG) for the 
best confrontational positions of the tested compounds 
and a detailed analysis of the geometric location of the 
leading compounds in the active sites of these receptors. 
 
3. Materials and methods of research 
The generation of the database for virtual 
screening was performed using the program Marvin 
Sketch 20.5.  
Autodock 4.2 software package was used for re-
ceptor-oriented flexible docking. Preparation of ligands 
was performed using the program MGL Tools 1.5.6. 
Optimization of ligands was performed using the pro-
gram Avogadro. For calculations in Autodock 4.2. the 
original data formats of the receptor and ligands were 
converted to a special PDBQT format. Active centers of 
macromolecules from Protein Data Bank (PDB) of neu-
rotropic receptors (PDB ID: 5UOW, 5CXV, 6PV7) were 
used as biological targets for docking. Receptor maps 
were prepared in MGL Tools and AutoGrid. Water mol-
ecules, ions and ligand were removed from the PDB file 
ID:. The following docking parameters were set: the 
translational step was 2 Å, the torsional freedom coeffi-
cient was 0.2983. The cluster tolerance is 2 Å. External 
lattice energy – 1000, maximum initial energy – 0, max-
imum number of attempts – 10 000. Number of struc-
tures in the population – 150, maximum number of stag-
es of energy estimation – 2500000, maximum number of 
generations – 27 000, number of structures that pass to 
the next generation – 1, the level of gene  
mutation – 0.02, the level of the crossover – 0.8, the 
method of the crossover - arithmetic. The α-Gaussian 
distribution parameter is equal to 0, the β-parameter of 
Gaussian distribution is 1. Visual analysis of complexes 
of substances in the active center of receptors (PDB ID: 
5UOW, 5CXV, 6PV7) was performed using Discovery 
Studio Visualizer.  
 
4. Research results 
The object of the study was selected promising 
nootropic molecules from the group of racetams - new 
derivatives of 1-benzyl-4-pyrrolidin-2-one. At the first 
stage of a purposeful search for new nootropic BAS by 
structural modification of the basic structure of 1-benzyl-
4-pyrrolidin-2-one by combination through position C4 
with a substituted 1,2,4-triazole system using the pro-
gram Marvin Sketch 20.5. Was generated a virtual data-
base of new compounds in the amount of approximately 





The introduction of a fragment of 1,2,4-triazole-5-
thione (a potential electron pair donor) into the basic 
structure of 1-benzyl-4-pyrrolidin-2-one should promote 
the formation of hydrogen bonds with the hydrogen at-
oms of the biotarget with a sufficient partial charge. 
Functionalization of the basic structure of 1-benzyl-4- (4-
R-5-sulfonylidene-4,5-dihydro-1H-1,2,4-triazol-3-yl) 
pyrrolidin-2-one is provided by additional introduction in 
position C1 and C4 1,2,4-triazole ring aromatic and het-
erocyclic moieties that may increase activity. The intro-
duction of alkyl chains of different lengths between the 
1,2,4-triazole ring and the corresponding substituents 
should ensure optimal lipophilicity of the molecules, 
which is an important factor in the search for BAS, 
which must pass through the GEB. 
According to the results of 3D-pharmacophore 
screening and molecular docking to nootropic targets of 
compounds of the virtual base, a promising group of 
compounds was identified – derivatives of 1-benzyl-4- 
(4-R-5-sulfanilidene-4,5-dihydro-1H-1,2, 4-triazol-3-yl) 
pyrrolidin-2-one, which have affinity for nootropic 
targets. In the tab. 1 scoring functions are given, which 
indicate the enthalpy contribution to the value of free 
binding energy (Afinity DG) for the best conformation-
al positions of all compounds of the selected perspec-
tive group. 
An analysis of the geometric location in the active 
sites of nootropic receptors of “hit compounds” 2 and 11 
(Fig. 1), which allowed to formulate some hypotheses 
about possible ways of interaction of compounds of the 
generated base with biotargets.   
 
n
n = 0, 1, 2




The value of Afinity DG for the best conformational positions of 1-benzyl-4- (4-R-5-sulfonylidene-4,5-dihydro-1H-
1,2,4-triazol-3-yl) pyrrolidin-2-one in the complex with neurotropic targets (PDB ID: 5UOW, 5CXV, 6PV7) 
No. Structure Afinity DG, kcal/mol 
5UOW 5CXV 6PV7 
























–6.4 –8.1 –6.0 
 




Continuation of Table 1 
1 2 3 4 5 
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–7.1 –8.5 –6.5 
8 
 
–7.4 –8.5 –6.2 
9 
 
–7.4 –8.8 –6.6 
10 
 
–6.5 –7.8 –5.8 
11 
 
–9.2 –9.9 –7.5 
12 
 
–6.5 –7.8 –6.2 
 
 
Scientific Journal «ScienceRise: Pharmaceutical Science»                                                                     №4 (26)2020 
 
9 
Continuation of Table 1 
1 2 3 4 5 
13 
 
–7.8 –8.0 –6.7 
14 
 
–7.7 –9.4 –6.6 
15 
 
–7.9 –8.9 –6.7 
16 
 
–7.3 –8.2 –6.1 
17 
 
–8.6 –9.9 –7.5 
18 
 
–7.5 –8.7 –7.1 
19 
 
–8.0 –8.7 –5.9 
 




Continuation of Table 1 




–8.9 –9.2 –7.1 
21 
 
–7.8 –8.6 –5.8 
22 
 
–7.3 –8.1 –6.2 
23 
 
–6.5 –7.6 –5.6 
24 
 
–6.4 –7.7 –6.4 
25 
 
–7.9 –8.9 –6.9 
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Continuation of Table 1 
1 2 3 4 5 
26 
 
–7.8 –7.7 –6.4 
27 
 
–7.7 –9.2 –7.0 
28 
 
–7.8 –7.8 –7.2 
29 
 
–8.0 –8.8 –7.4 
30 
 
–7.5 –9.2 –6.1 
31 
 
–7.2 –81 –6.3 
 
 





Fig. 1. Structures of hit compounds 
 
A detailed analysis of the geometric arrangement of 
molecule 2 at the active site of the N-methyl-d-aspartate 
receptor (NMDAR) (PDB ID: 5UOW) showed that the 
bonds between the fluorine atoms of the trifluoromethyl 
substituent and the amino acid donor Argin1 ARG are in-
volved in the formation of the complex. The presence of 
hydrogen bonds between the Nitrogen atom of the 1,2,4-
triazole ring and the ILE662 isoleucine residue also contrib-
utes to the stabilization of the formed complex.  
The formation and stabilization of the complex 
is facilitated by the π-σ bond that occurs between the 
aryl moiety and the residue of valine VAL540. Addi-
tionally stabilize the complex of π-Alk and Alk inter-
actions between aromatic fragments of the molecule 
and trifluoromethyl substituent with amino acid resi-
dues ILE544, ILE538, PHE677, LEU670, ALA726, 




Fig. 2. Superposition of molecule 2 and diagram of intermolecular interactions in complex with N-methyl-d-aspartate 






































Fig. 3. Superposition of molecule 11 and diagram of intermolecular interactions in complex with N-methyl-d-aspartate 
receptor (NMDAR) (PDB ID: 5UOW) 
 
 
Compound 11 forms a complex with the N-
methyl-d-aspartate receptor due to the π-σ bond between 
the phenyl moiety and VAL745 residues. Π-σ binding 
also occurs between the naphthyl moiety and the 
VAL540 residue. Stabilization of the π-Alk complex 
occurs due to the interaction between the naphthyl frag-
ment and amino acid residues ILE538, ALA726, 
VAL540, ARG661 (Fig. 3). 
The complex between molecule 2 and the musca-
rinic acetylcholine receptor (PDB ID: 5CXV) is formed 
due to the halogen bonds between the fluorine atoms of 
the trifluoromethyl substituent and the residues GLU401, 
TYR85, LEU86, the hydrogen bond between the oxygen 
atom of pyrrolidine-2one and the residue of TYR381.  
π-H The interaction occurs between the sulfur atom of 
the thionic group and the amino acid residue TYR404.  
π-Anionic and π-σ interactions are formed between the 
phenyl fragments of the molecule and the GLU401 and 
TYR179 residues. A carbon-hydrogen bond is also pre-
sent between the Fluorine atom and the glycine GLY89 
residue. Additional stabilization of the complex is facili-
tated by π-π, π-Alk and Alk interactions that occur be-
tween the leucine LEU88 residue and the phenyl ring of 
the studied molecule (Fig. 4). 
The formation of a complex of molecule 11 with 
acetylcholine receptor (PDB ID: 5CXV) involves a hy-
drogen bond (occurs between the nitrogen atom of 1,2,4-
triazole ring and the tyrosine residue TYR381) and the π-
anionic interaction between the phenyl ring and the glu-
tamine acid GLU401. 
Intermolecular π-π interactions occur between 
phenyl and naphthyl substituents with amino acid resi-
dues TYR85 and TYR400. Acceptor-acceptor binding is 
also observed between the Oxygen atom of pyrrolidin-2-
one and the TYR82 tyrosine residue. Additionally, the π-
Alk complex of interaction between the phenyl fragment 
of the molecule and the leucine residue LEU86 is stabi-
lized (Fig. 5). 
The complex of molecule 2 with the nicotinic ace-
tylcholine receptor (PDB ID: 6PV7) occurs due to the 
hydrogen bond between the Hydrogen of the 1,3,4-
triazole ring and the ILE85 residue. Also, a hydrogen 
bond is formed between the distal nitrogen atom of the 
1,2,4-triazole ring with the LYS87 residue. Halogen 
bonds are formed between the fluorine atom of trifluo-
romethyl and the amino acid residues of valine and as-
paragine (VAL102, ASP104). Hydrogen and carbon-
hydrogen bonds between the fluorine atom, the alkyl 
radical and the residues GLN101, LYS81, TYR151 also 
stabilize the formed complex. π-Cationic and π-anionic 
interactions occur between the phenyl rings of the mole-












Fig. 4. Superposition of molecule 2 and diagram of intermolecular interactions in complex with muscarinic  
acetylcholine receptor (PDB ID: 5CXV) 
 
 
Fig. 5. Superposition of molecule 11 and diagram of intermolecular interactions in complex with muscarinic  
acetylcholine receptor (PDB ID: 5CXV) 
 
Fig 6. Superposition of molecule 2 and diagram of intermolecular interactions in complex with nicotinic acetylcholine 
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Two π-σ bonds between phenyl and naphthyl 
rings for leucine residues are involved in the for-
mation of the complex of compound 11 with the nico-
tinic acetylcholine receptor (LEU468, LEU222). he  
π-sulfur interaction occurs between the sulfur atom of 
the thionic group and the PHE137 phenylalanine resi-
due.  Stabilization of the complex is facilitated by  
π-Alk interactions between aromatic fragments of the 
molecule and residues LEU468, LEU223, LEU465, 
ILE219 (Fig. 7).   
 
Fig 7. Superposition of molecule 11 and diagram of intermolecular interactions in complex with nicotinic acetylcholine 
receptor (PDB ID: 6PV7) 
 
5. Discussion of research results 
Piracetam and aniracetam are known pyrrolidine 
allosteric modulators [25, 26]. Previous research has 
already determined the structure of the ligand binding 
domain of glutamate receptor subtypes with piracetam 
and aniracetam. Both drugs bind in a very similar way, 
which indicates a slight specificity of the subunit. How-
ever, the binding sites of piracetam and aniracetam are 
significantly different. Aniracetam binds to a symmet-
rical region in the center of the dimeric interface. Pirace-
tam binds to several sites along a low-occupancy dimeric 
interface, one of which is a unique binding site for poten-
tial allosteric modulators. This new site may be important 
in the development of new allosteric regulators [27].  
The ability of racetams to act on glutamate recep-
tors leads to the activation of acetylcholine receptors. 
There is currently no data on their direct linking. There-
fore, the search for new nootropic molecules of this se-
ries that would have an affinity for these biotargets is an 
important area of docking research. 
The activity of promising molecules relative to the 
studied receptors (PDB ID: 5UOW, 5CXV, 6PV7) is real-
ized by the formation of complexes between them, the sta-
bility of which is ensured mainly by the energetically fa-
vourable geometric arrangement of ligands in the active 
center of these acceptors and the formation of hydrogen 
bonds between them, intermolecular electrostatic and donor-
acceptor interactions. As a result, the thermodynamic prob-
ability of such binding is confirmed by the negative values 
of the scoring functions (Afinity DG, kcal / mol) (Table 1). 
Given the detailed analysis of the geometric loca-
tion of “hit compounds” in the active sites of nootropic 
targets, the formation between them of a number of in-
termolecular interactions, calculated values of scoring 
functions, we can assume that the manifestation of affini-
ty for selected targets contribute: 
• the emergence of strong intermolecular hydro-
gen bonds between the compounds of the virtual base 
and the amino acid residues of the targets, 
• stabilization of the formed “target molecule” 
complex by intermolecular interactions with charge 
transfer (π-σ, π – Sulfur, π – anion, carbon-hydrogen 
bond, π– π, Alk and π – Alk). 
The formation and stabilization of complexes are 
provided by the modification of basic molecules with sul-
fonyl, the presence in their structure of alkyl-, oxy-, halo-
gen-substituted nitrogen-containing cyclic moieties and 
aromatic nuclei. Mandatory for the manifestation of activity 
is the presence in the structure of the methylene group be-
tween cycles, which provides flexibility of the molecule and 
allows it to occupy the most energetically advantageous 
conformational position in the active center of the biotarget. 
Study limitations. The possibility of using in sili-
co studies does not remove the relevance of in vivo stud-
ies, but has such advantages as cost-effectiveness, high 
reproducibility, no need for chemical synthesis of a huge 
number of compounds. 
Prospects for further researches. According to the 
results of the research, a group of 1-benzyl-4-(4-R-5-
sulfonylidene-4,5-dihydro-1H-1,2,4-triazol-3-yl) pyrrolidin-
2-one derivatives was found to have affinity for nootropic 
biotargets and promising for further synthetic studies.  
 
6. Conclusions 
An order to search for new molecules of nootropic 
action, a virtual base of 1-benzyl-4-pyrrolidin-2-one 
derivatives was generated and analyzed. 
According to the results of docking studies, a 
group of derivatives of 1-benzyl-4- (4-R-5-sulfonylidene-
4,5-dihydro-1H-1,2,4-tri-azol-3-yl) pyrrolidin-2-one was 
detected; they have an affinity for nootropic biotargets 













Structural fragments of new compounds have 
been identified, the presence of which increases the affin-
ity for nootropic biotargets. 
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